Navigation Links
Clinical Trial Participation Unaffected by Disclosure of Investigator's Financial Stake, Food and Drug Law Journal Article Finds
Date:12/18/2007

WASHINGTON, Dec. 18 /PRNewswire-USNewswire/ -- The willingness to participate in a clinical investigation of a new drug or device is not affected by the investigator's financial stake in the outcome of the trial, concludes a new study reported in an article in the latest issue of the Food and Drug Law Journal, published by the Food and Drug Law Institute.

Clinical studies are essential to obtain FDA approval of new drugs and certain devices. These studies are conducted by clinical investigators, who sometimes have a financial stake in the outcome of the clinical trial, or financial ties with the sponsor of the investigation. While there has been considerable discussion regarding when these financial interests must be disclosed to potential study participants -- and more broadly, when financial interests must be publicly disclosed -- the actual impact of this disclosure on potential study subjects has received much less attention.

Now, according to a study conducted by Gregory A. Guagnano, Ph.D., Associate Professor of Sociology and Anthropology at George Mason University (GMU) (Fairfax, Virginia) and Jeffrey N. Gibbs of Hyman, Phelps & McNamara, P.C. (Washington, DC), there's evidence that the investigator's financial stake in the trial may not be that important an issue for potential participants.

Guagnano and Gibbs asked 297 undergraduate students at GMU how likely they would be to agree to participate in a study involving a dietary supplement that might improve memory. Students were either told that the investigator was an employee of the company, that he was an employee and consultant, or that he was an employee and a patent holder. The study found that the willingness to participate was not affected by these three different conflict of interest disclosures. The study did find that students who rated the investigator as more trustworthy were more likely to agree to participate, but that the evaluation of trustworthiness was not influenced by the extent of the investigator's financial stake.

On the other hand, offering the students money did significantly affect their willingness to participate. Students who were told they would receive $20 were significantly more likely to want to participate than students offered no money.

Commented Guagnano, "The study suggests that learning about an investigator's financial stake may have a relatively limited impact on deciding whether to participate. If replicated, these findings could affect the way in which clinical study disclosure requirements are established and implemented."

Gibbs added, "There are a number of reasons to mandate disclosures, but this study suggests that disclosure of conflicts may not play a large role in decision-making. Given that some courts have reached decisions based on their believing that knowledge of a financial stake would actually change people's behavior, this study shows that courts need to rely on facts, not assumptions."

The article appears in Vol. 62, Issue 4 of the Food and Drug Law Journal.

For more information or to obtain a copy of the article, contact Michael Levin-Epstein, Editor-in-Chief, FDLI, (202) 222-0897; mdl@fdli.org

Founded in 1949, FDLI publishes the award-winning, peer-reviewed Food and Drug Law Journal; the bimonthly magazine Update; FDA Directory; and dozens of books and publications for attorneys, regulatory affairs practitioners, scientists, health care professionals, government employees and marketers in the food and drug field. For more information, visit http://www.fdli.org


'/>"/>
SOURCE Food and Drug Law Institute
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2017)... July 10, 2017 The Institute for In ... is the recipient of a VITROCELL® inhalation exposure system ... Science Consortium. The device, which is designed to replace ... human lung cells to airborne test materials in an ... the VITROCELL® system for testing combustible tobacco products, as ...
(Date:7/6/2017)... nutrition division of Diplomat Specialty Infusion Group, is celebrating a decade of ... To celebrate its anniversary, ThriveRx recently launched a redesigned website at ... organization to create the best user experience for consumers and health care ... Diplomat Pharmacy ... "We,ve made several great strides throughout the past 10 ...
(Date:7/5/2017)... July 5, 2017   BioLife Solutions , Inc. ... and marketer of proprietary clinical grade cell and tissue ... media ("BioLife"), today announced that it has reached an ... and largest shareholder, to modify its existing credit facility ... the modification, WAVI agreed to exchange its existing $4.25 ...
Breaking Medicine Technology:
(Date:7/21/2017)... (PRWEB) , ... July 21, 2017 , ... ... management assistance and financial planning services to families and business owners in northern ... event that promises to provide support to area adults with developmental challenges. , ...
(Date:7/21/2017)... , ... July 21, 2017 , ... ... and Theater of Witness , was awarded a $300,000 grant from ... program which fosters empathy, comfort with ambiguity and the recognition of one’s own ...
(Date:7/21/2017)... ... ... Overseer at The House of Yahweh in Abilene, Texas, has written a new post this ... world leaders to be more open about positive changes. Yisrayl says the use of force ... peaceful and positive way to solve all; yes, all issues, and he is ready to ...
(Date:7/21/2017)... , ... July 21, 2017 , ... ... Nature’s Tears® EyeMist®, the signature product of her research center at Bio-Logic Aqua ... world’s largest population and the greatest number of sufferers of blindness. “We think ...
(Date:7/21/2017)... ... July 21, 2017 , ... How physicians and athletic trainers ... say researchers presenting their work at the American Orthopaedic Society for Sports ... evaluating the patterns of change in concussion symptom presentation, diagnostic tools used and ...
Breaking Medicine News(10 mins):